Cannabis-Based Product Proven To Be As Effective As Melatonin For Sleep In Large-Scale Study

In a pioneering study recently published in the journal Pharmaceuticals, researchers have validated the effectiveness and safety of FloraWorks’ TruCBN in improving sleep quality. This study, conducted by Radicle Science, represents a significant milestone in cannabinoid research, marking the first time a cannabinoid has been clinically proven to enhance sleep quality in a large-scale, randomized, double-blind, placebo-controlled trial involving more than 1,000 participants.

A Significant Step In Cannabinoid Sleep Research

The study assessed the impact of three different doses of TruCBN (25 mg, 50 mg, and 100 mg) on sleep quality, comparing the results to those of a placebo and a standard 4 mg dose of melatonin. The 1,000 participants were diverse in gender, race and age provided a robust dataset for analysis.

Key Findings:

• Participants taking 50 mg of TruCBN experienced significantly improved sleep quality compared to those on the placebo.
• No significant differences in sleep improvement were observed between the TruCBN groups and the melatonin group, indicating TruCBN is as effective as melatonin.
• Side effects were mild and comparable across all groups, including the placebo, with grogginess and drowsiness being the most commonly reported.

Dr. Emily K. Pauli, the study’s principal investigator and chief research officer at Radicle Science, highlighted the significance of these findings. “This research represents a significant advancement in sleep science. Our findings suggest that TruCBN can effectively enhance sleep quality, providing a natural and safe alternative for those struggling with sleep disturbances, and an effective alternative to melatonin.”

Cannabinol (CBN), a minor phytocannabinoid, has gained popularity as a sleep aid due to anecdotal evidence suggesting its efficacy. The results showed that participants taking 100 mg of TruCBN experienced a larger decrease in stress levels compared to the placebo group. However, no significant differences were observed in anxiety, pain or overall well-being.

Addressing A Pressing Need

According to the CDC, one in three Americans suffers from sleep issues, hence the pressing need for effective and safe sleep aids. The global sleep aid market is projected to reach $114 billion by 2025, driven by increasing awareness of sleep disorders and the demand for new solutions.

“This publication is a testament to our commitment to advancing scientific understanding and clinical validation of cannabinoids,” said Alleh Lindquist, CEO of FloraWorks. “This marks a major step forward in our efforts to bring TruCBN into mainstream markets as a safe and effective alternative in the fight against sleeplessness.”

The findings of this study provide a compelling case for the inclusion of TruCBN in the array of available sleep aids. As a safe and effective alternative, TruCBN could offer relief to millions of individuals suffering from sleep disturbances, contributing to improved overall well-being.

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cover image made with AI